Dataset features

Specifications


Application: RNA-seq analysis
Number of samples: 864
Release date: Oct 19 2018
Last update date: Nov 29 2018
Access: Public
Diseases: Breast Neoplasms, Neoplasms
Chemicals: Estrogens, Tamoxifen
Dataset link Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies

Experimental Protocol


Examination of the transcriptional output (mRNA) of the HER2 activating mutations compared with controls under various drugs. Specifically, we expressed the activating mutations S653C, L755S, V777L, and L869R in ER+/HER2- breast cancer cell line (T47D), and controls (GFP, wild-type HER2, kinase-dead HER2, and ESR1 Y537S). Cell were then treated with DMSO, 1μM fulvestrant, 1μM neratinib, 10μM palbociclib, 1μM fulvestrant + 1μM neratinib, or 1μM fulvestrant + 10μM palbociclib for 24 hours. All experimental conditions were done in 6 replicates, sequenced in 3 replicates

Repositories


GEO

GSE121411

ENA

SRP166112

BioProject

PRJNA497449

Download


Contact


Ofir Cohen